Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Barth Syndrome-Pipeline Review, H2 2018, provides an overview of the Barth Syndrome (Other Diseases) pipeline landscape.
Barth syndrome is a rare disorder characterized by dilated cardiomyopathy, skeletal myopathy, recurrent infections due to neutropenia, and short stature. It is passed from mother to son through the X chromosome. Symptoms include cardiomyopathy, skeletal muscle abnormalities, weak muscle tone, increased levels of organic acids in blood and urine and frequent bacterial infections such as pneumonia. This occurs exclusively in male. Treatment includes physical therapy to help with reduced muscle tone and antibiotics for bacterial infections.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Barth Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Barth Syndrome (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Barth Syndrome (Other Diseases) pipeline guide also reviews of key players involved in therapeutic development for Barth Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Barth Syndrome (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The pipeline guide provides a snapshot of the global therapeutic landscape of Barth Syndrome (Other Diseases). The pipeline guide reviews pipeline therapeutics for Barth Syndrome (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Barth Syndrome (Other Diseases) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Barth Syndrome (Other Diseases) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Barth Syndrome (Other Diseases)
To know more click on the link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/barth-syndrome-review/153177-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91 9015378249
